Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDELIFE: ER004 for Prenatal Treatment of XLHED
NCT04980638Phase 2Recruiting
- Sponsor
- EspeRare
- Start
- Apr 2022
- Primary completion
- Feb 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 2, open-label trial of EDI200 in X-linked hypohidrotic ectodermal dysplasia (XLHED) (2 arms), sponsored by EspeRare. Primary endpoint: Mean sweat volume at 6 months. Started Apr 2022; status: recruiting.
02
Drugs
EDI200
03
Conditions
X-linked hypohidrotic ectodermal dysplasia (XLHED)
Beyond the preview
Go deeper on NCT04980638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980638.